Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Solid Tumors 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 110fludarabine phosphate 106Busulfan 84Azacitidine 73Peripheral Blood Stem Cell Transplantation 64Mycophenolic Acid 64Antilymphocyte Serum 64Cytarabine 63Tacrolimus 62fludarabine 61Cyclosporine 56Filgrastim 55Whole-Body Irradiation 52Methotrexate 47Melphalan 42Decitabine 42Radiotherapy 37Clofarabine 29Granulocyte Colony-Stimulating Factor 28Cord Blood Stem Cell Transplantation 28Methylprednisolone 24Etoposide 24thymoglobulin 21Thiotepa 21Stem Cell Transplantation 21sargramostim 19Sirolimus 16Alemtuzumab 15Lenalidomide 13Gemtuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myelodysplastic Syndromes × CB-839 × Clear all
NCT03047993 2024-05-14

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Completed
28 enrolled 8 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡